A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06212999 · tracked via the Priya Life Science UK tracker

Sponsor

Incyte Corporation

Phase

Phase 3

Started

2024-01-30

Last updated

2026-08-25

Condition(s) studied

Hidradenitis Suppurativa (HS)

Investigational drug(s) / intervention(s)

Povorcitinib

Povorcitinib: Oral; Tablet

Study summary

The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Completion of the study treatment period of the originating parent study (INCB 54707-301 or INCB 54707-302). * Agreement to use contraception. * Willing and able to comply with the study protocol and procedures. * Further inclusion criteria apply. Exclusion Criteria: * Participation in the extension study could expose the participant to an undue safety risk. * Women who are pregnant (or who are considering pregnancy) or breastfeeding. * Further exclusion criteria apply.

Primary outcome measure(s)

Proportion of participants with Treatment-Emergent Adverse Events (TEAEs) — up to approximately 56 weeks
TEAE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug-related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug.

Trial sites (165)

Facility	City	Region
Investigative Site US303	Phoenix	Arizona
Investigative Site US240	Scottsdale	Arizona
Investigative Site US307	Fort Smith	Arkansas
Investigative Site US214	Rogers	Arkansas
Investigative Site US315	Laguna Niguel	California
Investigative Site US223	Los Angeles	California
Investigative Site US222	Oakland	California
Investigative Site US226	San Diego	California
Investigative Site US309	Clearwater	Florida
Investigative Site US317	Hialeah	Florida
Investigative Site US306	Hollywood	Florida
Investigative Site US320	Hollywood	Florida
Investigative Site US316	Maitland	Florida
Investigative Site US227	Margate	Florida
Investigative Site US204	Miami	Florida
Investigative Site US236	Miami	Florida
Investigative Site US321	North Miami Beach	Florida
Investigative Site US200	Ocala	Florida
Investigative Site US228	Tampa	Florida
Investigative Site US201	Tampa	Florida
Investigative Site US311	Marietta	Georgia
Investigative Site US220	West Dundee	Illinois
Investigative Site US206	Indianapolis	Indiana
Investigative Site US337	Indianapolis	Indiana
Investigative Site US341	Bowling Green	Kentucky
Investigative Site US209	Louisville	Kentucky
Investigative Site US305	Baton Rouge	Louisiana
Investigative Site US207	Metairie	Louisiana
Investigative Site US229	New Orleans	Louisiana
Investigative Site US224	Baltimore	Maryland
Investigative Site US325	Marriottsville	Maryland
Investigative Site US225	Boston	Massachusetts
Investigative Site US304	Boston	Massachusetts
Investigative Site US310	Brighton	Massachusetts
Investigative Site US221	Quincy	Massachusetts
Investigative Site US213	Fort Gratiot	Michigan
Investigative Site US217	Waterford	Michigan
Investigative Site US212	Minneapolis	Minnesota
Investigative Site US302	St Louis	Missouri
Investigative Site US318	Portsmouth	New Hampshire

+ 125 more sites — see the full list on the official registry below.

More Incyte Corporation trials in the UK

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) Recruiting

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) Active, not recruiting

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders Recruiting

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) Active, not recruiting

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients Active, not recruiting

Other trials for the same condition

A Study With CIT-013 in HS Patients Recruiting

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06212999 on ClinicalTrials.gov ↗ ← All trials in the UK